4'-氨基甲酰-4-联苯基羧酸 | 166386-38-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4'-氨基甲酰-4-联苯基羧酸
• 中文别名: 1-萘羧酸,1-氨基-1,2,3,4-四氢-,甲基酯(9CI)
• 英文名称: 4-(4-carbamoyl-phenyl)-benzoic acid
• 英文别名: 4-(4-carbamoylphenyl)benzoic Acid
• CAS: 166386-38-5
• 化学式: C₁₄H₁₁NO₃
• 分子量: 241.246
• InChiKey: QHLNIHHGHTXGDF-UHFFFAOYSA-N

物化性质

• 沸点：
  490.0±38.0 °C(Predicted)
• 密度：
  1.297±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4'-氨基甲酰-4-联苯基羧酸 、 [R-(R,R)]-a-(1-氨乙基)-3-氰基-苯丙酸甲酯 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Optimization of the β-Aminoester class of factor Xa inhibitors. part 1: P4 and side-Chain modifications for improved In vitro potency

  摘要：

  A systematic modification of the C3 side-chain of the beta-aminoester class of factor Xa inhibitors and a survey Of P-4 variations is described. These changes have resulted in the identification of sub-nanomolar inhibitors with improved selectivity versus related proteases. Coagulation parameters (i.e., APTT doubling concentrations) are also improved. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00212-3
• 作为产物：
  描述：

  对溴苯甲胺 、 4-羧基苯硼酸频那醇酯 在 四(三苯基膦)钯 、 三氟乙酸 、 Wang resin 作用下， 生成 4'-氨基甲酰-4-联苯基羧酸
  参考文献：
  名称：

  NMR-Based Discovery of Lead Inhibitors That Block DNA Binding of the Human Papillomavirus E2 Protein

  摘要：

  The E2 protein is required far the replication of human papillomaviruses (HPVs), which are responsible for anogenital warts and cervical carcinomas, Using an NMR-based screen, we tested compounds for binding to the DNA-binding domain of the HPV-E2 protein. Three classes of compounds were identified which bound to two distinct sites on the protein. Biphenyl and biphenyl ether compounds containing a carboxylic acid bind to a site near the DNA recognition helix and inhibit the binding of E2 to DNA. Benzophenone-containing compounds which lack a carboxylic acid group bind to the beta-barrel formed by the dimer intel face and exhibit negligible effects on the binding of E2 to DNA. Structure-activity relationships from the biphenyl and biphenyl ether compounds were combined to produce a compound [5-(3'-(3 '',5 ''-dichlorophenoxy)phenyl)-2,4-pentadienoic acid] with an IC50 value of approximately 10 mu M. This compound represents a useful lead for the development of antiviral agents that interfere with HPV replication and further illustrates the usefulness of the SAR by NMR method in the drug discovery process.

  DOI：

  10.1021/jm9703404

文献信息

• BICYCLIC HETEROCYCLIC COMPOUND
  申请人：Astellas Pharma Inc.

  公开号：US20140249151A1

  公开（公告）日：2014-09-04

  [Problem] To provide a compound useful as an active ingredient of a pharmaceutical composition for treating 11β-hydroxysteroid dehydrogenase type 1-related diseases such as dementia, schizophrenia, depression, pain (particularly, neuropathic pain or fibromyalgia), diabetes (particularly, type II diabetes mellitus), insulin resistance and the like. [Means for Solution] A bicyclic heterocyclic compound (the bicyclic heterocycle is formed when a cyclohexane ring is fused with a 5- to 6-membered monocyclic heterocycle that has only a nitrogen atom as a hetero atom) substituted with an acylamino group such as a (hetero)aroylamino group or the like or a pharmaceutically acceptable salt thereof was found to have an excellent selective inhibitory action against 11β-HSD1. Accordingly, the bicyclic heterocyclic compound of the present invention can be used for treating dementia, schizophrenia, depression, pain (particularly, neuropathic pain or fibromyalgia), diabetes (particularly, type II diabetes mellitus), insulin resistance, and the like.

  提供一种化合物，作为药物组合物的有效成分，用于治疗与11β-羟基类固醇脱氢酶1相关的疾病，如痴呆症、精神分裂症、抑郁症、疼痛（尤其是神经病性疼痛或纤维肌痛）、糖尿病（尤其是2型糖尿病）、胰岛素抵抗等。解决方法是发现一种带有酰胺基（如（杂）芳酰胺基等）或其药用可接受盐的取代的双环杂环化合物（当环己烷环与仅有氮原子作为杂原子的5-至6-成员单环杂环融合时形成双环杂环化合物），发现其对11β-HSD1具有出色的选择性抑制作用。因此，本发明的双环杂环化合物可用于治疗痴呆症、精神分裂症、抑郁症、疼痛（尤其是神经病性疼痛或纤维肌痛）、糖尿病（尤其是2型糖尿病）、胰岛素抵抗等。
• Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US20030153604A1

  公开（公告）日：2003-08-14

  This invention is directed to an (aminoiminomethyl or aminomethyl)benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

  本发明涉及一种公式I的(氨基亚甲基或氨基甲基)苯并杂环化合物，该化合物通过与含有Xa因子的组合物结合来抑制Xa因子的活性。本发明还涉及含有公式I化合物的组合物、它们的制备方法以及它们的用途，例如抑制凝血酶的形成或治疗患有或受到与生理上有害的过量凝血酶相关的疾病状态的患者。
• Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors
  申请人：Angell Martyn Richard

  公开号：US20050065195A1

  公开（公告）日：2005-03-24

  Compounds of formula (I), wherein R3 is the group; or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.

  式(I)的化合物，其中R3为该基团；或其药学上可接受的盐或溶剂合物，并且它们可用作药物，特别是作为p38激酶抑制剂。
• ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS
  申请人：Yamagishi Tatsuya

  公开号：US20120232052A1

  公开（公告）日：2012-09-13

  The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar 1 is phenyl; Ar 2 is aryl; n is 1-4; X is —O—, —S—, —SO— or —SO 2 —, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of such disorders and diseases as pain in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases as pain in which voltage gated sodium channels are involved.

  本发明涉及公式（I）的芳基羧酰胺衍生物，其中Ar1是苯基；Ar2是芳基；n为1-4；X为—O—、—S—、—SO—或—SO2—，其前体药物或其药学上可接受的盐，具有阻断电压门控钠通道如TTX-S通道的活性，并在治疗或预防涉及电压门控钠通道的疾病和疾病，如疼痛方面中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病和疾病，如疼痛方面的使用。
• Amido-(propyl and allyl)-hydroxybenzamidines: development of achiral inhibitors of factor Xa
  作者：Yong Gong、Henry W. Pauls、Alfred P. Spada、Mark Czekaj、Guyan Liang、Valeria Chu、Dennis J. Colussi、Karen D. Brown、Jingbo Gao

  DOI：10.1016/s0960-894x(99)00673-3

  日期：2000.2

  The design, synthesis and SAR of amido-(propyl and allyl)-hydroxybenzamidine coagulation factor Xa inhibitors is described. These achiral inhibitors are selective for fXa vis a vis structurally related serine proteases and are readily prepared in 6-7 linear steps. The most potent member 9j (fXa K-i = 0.75 nM) is selective (>1000-fold) and an effective anticoagulant in mammalian plasma. (C) 2000 Elsevier Science Ltd. All rights reserved.